… This review mainly focuses on the level one evidence-based clinical efficacy and drug-related
toxicity of oral PDE5Is. In addition, drug discovery, pharmacokinetics and …

… clinical study data, efficacy for the three PDE5 inhibitors for the treatment of ED is
comparable.Because direct clinical … drawn about the relative efficacy of the PDE5 inhibitors. In one …

… xii) Participation in other clinical studies in the previous 3 months. xiii) A history of allergies
to specific phosphodiesterase inhibitors or contraindications for the use of such drugs, …

… and clinical efficacy of PDE4 inhibitors, which have been in clinical development over the …
On the basis of its clinical effectiveness in COPD, roflumilast has recently received market …

… Theophylline and papaverine have historically been used therapeutically and are known
to be weak inhibitors of PDE, but to what extent this contributed toward their clinical efficacy …

… clinical efficacy in vivo. In addition, because of overlapping affinities with other PDEs, each
PDE5 inhibitor … of the PDE5 inhibitors, and after four years of widespread clinical use is widely …

… Some instruments for comparison of clinical efficacy have to be considered subjective (psychometry,
patient’s preference, changes in quality of general, or sexual life). Some others are …

… of thumb the clinical efficacy of the respective PDE5 inhibitors … efficacy and side-effects may
be differently perceived in the same individual patient with each of the three PDE5 inhibitors …

… of phosphodiesterase inhibitors. We also review data on the efficacy and safety of two
phosphodiesterase 4 inhibitors - apremilast and AN2728- that have exhibited efficacy in studies of …

… inhibitors in mediating cardioprotection. We then examine clinical trials investigating PDE5
inhibition … show positive results and efficacy with PDE5 inhibition despite no safety concerns. …